This technology, offered for licensing, provides a novel and potentially non-toxic approach to treat a wide range of cancers using RNA Inhibitors.
Available for Licensing or Sale. Developed by a doctor with extensive experience in treating patients with eczema, psoriasis, and dry, itchy or infected skin.
These biocompatible, non-toxic nanospheres are 20-80 nm in size and due to their hydrophilc-hydrophobic nature, are ideally suited for encapsulating drugs.
Tech-9094a: Licensing Opportunity: Endotoxin-binding Compounds for Sepsis (Orphan Drug Approval Pending)
The company is likely to get an Orphan Drug Approval in Jan, 2020 for these unique molecules that provide effective treatment for sepsis (for which currently there is no treatment. A unique opportunity...